What's new in molecular genetic pathology 2026: emerging biomarkers for personalized cancer therapies

New and emerging biomarkers and current molecular assays for the most prevalent and lethal cancers worldwide-breast, lung, prostate, and colorectal cancer-are described. Notably, HER2-low breast cancer and HER2-mutated non-small cell lung cancer have recently been recognized as targetable entities. In addition, various tissue-based analyses are now available to assess prognosis and the risk of relapse in prostate cancer.

Authors

Institutions

Publication Details

Journal
Journal of Pathology and Translational Medicine
Published
2026-01-03
DOI
https://doi.org/10.4132/jptm.2026.01.03
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

What's new in molecular genetic pathology 2026: emerging biomarkers for personalized cancer therapies

Umberto Maccio
Journal of Pathology and Translational Medicine
Cancer Genomics and Diagnostics
article

What's new in molecular genetic pathology 2026: emerging biomarkers for personalized cancer therapies

Umberto Maccio
article en

Abstract

New and emerging biomarkers and current molecular assays for the most prevalent and lethal cancers worldwide-breast, lung, prostate, and colorectal cancer-are described. Notably, HER2-low breast cancer and HER2-mutated non-small cell lung cancer have recently been recognized as targetable entities. In addition, various tissue-based analyses are now available to assess prognosis and the risk of relapse in prostate cancer.

Journal of Pathology and Translational MedicineVol. 60(2)
University Hospital of Zurich (CH)
Openalex Percentile: Top 71%
Cancer Genomics and Diagnostics
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

What's new in molecular genetic pathology 2026: emerging biomarkers for personalized cancer therapies — Umberto Maccio · Journal of Pathology and Translational Medicine (2026) | TGRS Research Map | TGRS